The city of Montclair will require employees to wear stickers proving they are fully vaccinated against COVID-19 if they don’t want to wear a mask while working.

Starting Monday, city workers who choose to shed their masks will be required to wear a sticker showing they’ve received a COVID-19 vaccine, officials said.

In June, the Occupational Safety and Health Standards Board voted 5 to 1 to allow most fully vaccinated employees in many workplaces to stop wearing masks. However, Cal/OSHA also ruled that employers have to document the vaccination status of employees if they’re going to go without face coverings indoors, although they don’t have to retain copies of vaccine cards and employees can also self-attest to their inoculation status.

When do the boxcars arrive?

https://www.latimes.com/california/story/2021-07-23/montclair-unmasked-workers-must-wear-covid-vaccine-stickers

Flu returns January 1, 2022

https://www.cdc.gov/csels/dls/locs/2021/07-21-2021-lab-alert-Changes_CDC_RT-PCR_SARS-CoV-2_Testing_1.html

Audience: Individuals Performing COVID-19 Testing

Level: Laboratory Alert

After December 31, 2021, CDC will withdraw the request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel, the assay first introduced in February 2020 for detection of SARS-CoV-2 only. CDC is providing this advance notice for clinical laboratories to have adequate time to select and implement one of the many FDA-authorized alternatives.

Visit the FDA website for a list of authorized COVID-19 diagnostic methods. For a summary of the performance of FDA-authorized molecular methods with an FDA reference panel, visit this page.

In preparation for this change, CDC recommends clinical laboratories and testing sites that have been using the CDC 2019-nCoV RT-PCR assay select and begin their transition to another FDA-authorized COVID-19 test. CDC encourages laboratories to consider adoption of a multiplexed method that can facilitate detection and differentiation of SARS-CoV-2 and influenza viruses. Such assays can facilitate continued testing for both influenza and SARS-CoV-2 and can save both time and resources as we head into influenza season. Laboratories and testing sites should validate and verify their selected assay within their facility before beginning clinical testing.